<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Collaboration</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Insilico Medicine and Aska enter gynecological collaboration</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729879</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Gynecology-womens-health-female-reproductive-system.webp?t=1774455533" type="image/jpeg" medium="image" fileSize="650388">
        <media:title type="plain">Futuristic medical hologram illustration featuring the female reproductive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Insitro and Bristol Myers Squibb expand ALS collaboration</title>
      <description>
        <![CDATA[Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/729858</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729858-insitro-and-bristol-myers-squibb-expand-als-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Demyelination-of-a-neuron.webp?t=1687357719" type="image/jpeg" medium="image" fileSize="237601">
        <media:title type="plain">Demyelination of a neuron</media:title>
      </media:content>
    </item>
    <item>
      <title>Glyconex and Nippon Kayaku collaborate on GNX201-ADC</title>
      <description>
        <![CDATA[Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729857</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729857-glyconex-and-nippon-kayaku-collaborate-on-gnx201-adc</link>
    </item>
    <item>
      <title>New Danish research program targets α-synuclein in Parkinson’s</title>
      <description>
        <![CDATA[A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729792</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729792-new-danish-research-program-targets-synuclein-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Alpha-synuclein.webp?t=1719584612" type="image/jpeg" medium="image" fileSize="77677">
        <media:title type="plain">3D structure model of α-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Alloy Therapeutics and Abbvie partner on antibody platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729674</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729674-alloy-therapeutics-and-abbvie-partner-on-antibody-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Aptar and Covirix Medical collaborate on inhaled antivirals</title>
      <description>
        <![CDATA[Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729629</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729629-aptar-and-covirix-medical-collaborate-on-inhaled-antivirals</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Virus-and-drug-illustration.webp?t=1637179016" type="image/png" medium="image" fileSize="294622">
        <media:title type="plain">Virus and drug illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Newcelx partners with Eledon to advance NCEL-101</title>
      <description>
        <![CDATA[Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729416</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729416-newcelx-partners-with-eledon-to-advance-ncel-101</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Insulin-glucose-endocrine-metabolim.webp?t=1673451854" type="image/png" medium="image" fileSize="678616">
        <media:title type="plain">Diagram of how cells take up glucose from the stomach and insulin from the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Zelluna, Etcembly partner on AI-enabled T-cell receptor engineering</title>
      <description>
        <![CDATA[Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729415</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729415-zelluna-etcembly-partner-on-ai-enabled-t-cell-receptor-engineering</link>
    </item>
    <item>
      <title>Sinopia and Ono collaborate in metabolic disorders</title>
      <description>
        <![CDATA[Sinopia Biosciences Inc. has entered into a target discovery collaboration with Ono Pharmaceutical Co. Ltd. focused on a group of rare metabolic disorders with significant unmet medical need.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729328</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729328-sinopia-and-ono-collaborate-in-metabolic-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/human-body-metabolism.webp?t=1726239536" type="image/jpeg" medium="image" fileSize="320060">
        <media:title type="plain">Art concept for metabolism</media:title>
      </media:content>
    </item>
    <item>
      <title>Antiverse announces series A financing, tie-up with CF Foundation</title>
      <description>
        <![CDATA[Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729324</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729324-antiverse-announces-series-a-financing-tie-up-with-cf-foundation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Ono and Congruence expand drug discovery collaboration</title>
      <description>
        <![CDATA[Ono Pharmaceutical Co. Ltd. has entered into an agreement to expand its drug discovery collaboration agreement with Congruence Therapeutics Inc. for the discovery of novel small-molecule modulators against multiple protein targets in the areas of neurology and immunology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729155</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729155-ono-and-congruence-expand-drug-discovery-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/business-strategy-development.webp?t=1588793925" type="image/png" medium="image" fileSize="1357286">
        <media:title type="plain">Blocks with gears, lightbulb, target, magnifying glass </media:title>
      </media:content>
    </item>
    <item>
      <title>Cure Rare Disease signs ANO5-related disease partnership</title>
      <description>
        <![CDATA[Cure Rare Disease has entered into a multiyear partnership with the LGMD2L Foundation to develop a gene replacement therapy for anoctamin 5 (ANO5)-related disease, a rare genetic disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729153</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729153-cure-rare-disease-signs-ano5-related-disease-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-dollars.webp?t=1588782408" type="image/png" medium="image" fileSize="377807">
        <media:title type="plain">DNA, dollars illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Angelini and Quiver Bioscience partner in genetic epilepsies</title>
      <description>
        <![CDATA[Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729017</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729017-angelini-and-quiver-bioscience-partner-in-genetic-epilepsies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA2.webp?t=1663611764" type="image/png" medium="image" fileSize="254381">
        <media:title type="plain">Brain and DNA </media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Gelmedix supports GMX-101 for geographic atrophy</title>
      <description>
        <![CDATA[Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728920</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Nektar Therapeutics and UCSF explore TNFR2 agonism in MS</title>
      <description>
        <![CDATA[Nektar Therapeutics Inc. has established an academic research collaboration with the University of California, San Francisco (UCSF) to explore the role of tumor necrosis factor receptor 2 (TNFR2) agonism in models of multiple sclerosis (MS) with the aim of supporting progression of NKTR-0165, Nektar’s first-in-class TNFR2 agonist antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728918</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728918-nektar-therapeutics-and-ucsf-explore-tnfr2-agonism-in-ms</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/research-collaboration-deal-handshake-gloves.webp?t=1765812758" type="image/jpeg" medium="image" fileSize="419449">
        <media:title type="plain">Photo of researchers shaking hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Teijin Pharma and Aska partner in gynecological diseases</title>
      <description>
        <![CDATA[Teijin Pharma Ltd. has entered into a joint research agreement with Aska Pharmaceutical Co. Ltd. to jointly develop novel small-molecule drug candidates for gynecological diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728899</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728899-teijin-pharma-and-aska-partner-in-gynecological-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-reproduction-ovaries-uterus-cervix.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="118515">
        <media:title type="plain">Illustration of women's reproductive organs</media:title>
      </media:content>
    </item>
    <item>
      <title>Advancell and 48Hour Discovery partner on 212Pb radiotherapeutic</title>
      <description>
        <![CDATA[Advancell Pty Ltd. has entered into a collaboration and exclusive licensing agreement with 48Hour Discovery Inc. to develop a novel peptide-based lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728512</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728512-advancell-and-48hour-discovery-partner-on-212pb-radiotherapeutic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Radiotherapy-of-cancer.webp?t=1666626496" type="image/png" medium="image" fileSize="567967">
        <media:title type="plain">Radiotherapy of cancer </media:title>
      </media:content>
    </item>
    <item>
      <title>Astrazeneca and CSPC collaborate in obesity and type 2 diabetes</title>
      <description>
        <![CDATA[Astrazeneca plc has signed a new strategic collaboration agreement with CSPC Pharmaceutical Group Ltd. to advance the development of next-generation therapies for obesity and type 2 diabetes across eight programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728438</guid>
      <pubDate>Fri, 30 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728438-astrazeneca-and-cspc-collaborate-in-obesity-and-type-2-diabetes</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-puzzle-pieces.webp?t=1588276668" type="image/png" medium="image" fileSize="174585">
        <media:title type="plain">Connecting puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Sinorda Biomedicine and Wuxi Biologics collaborate on SND-006</title>
      <description>
        <![CDATA[Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of inflammatory bowel disease and other autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728417</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728417-sinorda-biomedicine-and-wuxi-biologics-collaborate-on-snd-006</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>SCN2A Foundation and Unravel Biosciences collaborate</title>
      <description>
        <![CDATA[The SCN2A Foundation has entered into a research collaboration with Unravel Biosciences Inc. to advance preclinical research for SCN2A-related disorders caused by loss-of-function mutations, a subset of SCN2A conditions driven by insufficient functional protein.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728415</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728415-scn2a-foundation-and-unravel-biosciences-collaborate</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation.webp?t=1674229694" type="image/png" medium="image" fileSize="1464740">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Starkage and Gustave Roussy research cellular senescence</title>
      <description>
        <![CDATA[Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728379</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728379-starkage-and-gustave-roussy-research-cellular-senescence</link>
    </item>
    <item>
      <title>Mair Therapeutics and Radboud collaborate in Parkinson’s</title>
      <description>
        <![CDATA[Mair Therapeutics BV has established a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728376</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728376-mair-therapeutics-and-radboud-collaborate-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-brain-puzzle-alzheimers-parkinsons.webp?t=1745263787" type="image/jpeg" medium="image" fileSize="303211">
        <media:title type="plain">Elderly woman holding illustration of brain with missing puzzle piece</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer Ingelheim and Simcere partner on SIM-0709</title>
      <description>
        <![CDATA[Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728375</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728375-boehringer-ingelheim-and-simcere-partner-on-sim-0709</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/global-business-trade-deal.webp?t=1588276966" type="image/png" medium="image" fileSize="2119366">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Hygtia partner on ISM-8969</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco and Hygtia Therapeutics Co. Ltd. have entered into an exclusive license and co-development collaboration to advance ISM-8969 worldwide. ISM-8969 is an orally available, brain penetrant NLRP3 inhibitor for CNS disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728186</guid>
      <pubDate>Wed, 21 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728186-insilico-medicine-and-hygtia-partner-on-ism-8969</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-as-filament-in-light-bulb.webp?t=1695304772" type="image/jpeg" medium="image" fileSize="168302">
        <media:title type="plain">Brain as light bulb filament</media:title>
      </media:content>
    </item>
    <item>
      <title>Interax and Alveus Therapeutics partner in metabolic disease</title>
      <description>
        <![CDATA[Interax Biotech Ltd. and Alveus Therapeutics Inc. have signed a strategic research collaboration and licensing agreement to develop a differentiated small-molecule candidate for metabolic disease. Designed to overcome the limitations of current obesity medications, the candidate is expected to deliver durable weight loss with superior tolerability.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728031</guid>
      <pubDate>Fri, 16 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728031-interax-and-alveus-therapeutics-partner-in-metabolic-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/digital-human-body-with-molecules.webp?t=1729870096" type="image/jpeg" medium="image" fileSize="181884">
        <media:title type="plain">Illustration of human body composed of molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>Tahoe Therapeutics and Alloy Therapeutics form joint venture</title>
      <description>
        <![CDATA[Tahoe Therapeutics and Alloy Therapeutics Inc. are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers. The joint venture will advance two ADC programs directed at novel tumor targets discovered by Tahoe using its proprietary Mosaic platform and large-scale, perturbative single-cell datasets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727959</guid>
      <pubDate>Wed, 14 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727959-tahoe-therapeutics-and-alloy-therapeutics-form-joint-venture</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-antibody-attack.webp?t=1588880107" type="image/png" medium="image" fileSize="559822">
        <media:title type="plain">Antibodies attacking cancer cell </media:title>
      </media:content>
    </item>
    <item>
      <title>Swiss Rockets and Alloy Therapeutics form RLT partnership</title>
      <description>
        <![CDATA[Swiss Rockets AG and Alloy Therapeutics Inc. have signed a master research agreement establishing a multitarget collaboration to discover and develop next-generation radioligand therapeutics (RLTs) for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727937</guid>
      <pubDate>Tue, 13 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727937-swiss-rockets-and-alloy-therapeutics-form-rlt-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Hands-and-gears.webp?t=1590606316" type="image/png" medium="image" fileSize="377385">
        <media:title type="plain">Hands holding gears</media:title>
      </media:content>
    </item>
    <item>
      <title>Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s</title>
      <description>
        <![CDATA[Keiferx LLC has entered into a research collaboration and option agreement with Amneal Pharmaceuticals Inc. to support the pre-IND development of KFRX-06, Keiferx’s brain-penetrant preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727911</guid>
      <pubDate>Mon, 12 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727911-keiferx-collaborates-with-amneal-on-kfrx-06-for-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Shaky-hands-holding-glass.webp?t=1721855064" type="image/jpeg" medium="image" fileSize="74960">
        <media:title type="plain">Shaky hands holding glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Servier collaborate in cancer</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS focused on identifying and developing novel therapeutics for challenging targets in oncology by leveraging Insilico’s proprietary AI platform, Pharma.AI.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727643</guid>
      <pubDate>Mon, 05 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727643-insilico-medicine-and-servier-collaborate-in-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-pic.webp?t=1591653278" type="image/png" medium="image" fileSize="432362">
        <media:title type="plain">Digital cancer cells illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Harbour Biomed and Lannacheng Biotechnology form strategic collaboration</title>
      <description>
        <![CDATA[Harbour Biomed and Yantai Lannacheng Biotechnology Co. Ltd. have entered into a long-term strategic collaboration to jointly advance the development of next-generation radionuclide-drug conjugates for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727462</guid>
      <pubDate>Mon, 29 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727462-harbour-biomed-and-lannacheng-biotechnology-form-strategic-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Radiotherapy-radiation.webp?t=1730909547" type="image/jpeg" medium="image" fileSize="69291">
        <media:title type="plain">Hand holding radioactive symbol</media:title>
      </media:content>
    </item>
  </channel>
</rss>
